The short answer
Cancer clinical trials go through several layers of safety review before and during the study. Informed consent, Institutional Review Board approval, independent safety monitoring boards, and FDA oversight all work together to protect participants. Trials can even be stopped early if a treatment proves clearly effective or clearly ineffective.
Federally funded trials are reviewed by scientists before enrollment to ensure sound science.
Safety is protected through informed consent, protocol review and approval, and ongoing monitoring.
Institutional Review Boards (IRBs) review trial protocols before enrollment and at least yearly after.
Each IRB includes at least 5 members, including a scientist, a non-scientist, and someone unaffiliated with the site.
Choose how you want to understand this
The full explanation.
Safety review starts before you ever join
Cancer clinical trials that receive federal funding go through review by scientists before they're even allowed to enroll participants. This early review checks that a trial is built on sound science — in other words, that the study is designed well enough to actually answer the question it's asking, and that it's worth asking people to take part in.
Three layers of protection
Once a trial is underway, participant safety is protected through three main mechanisms working together:
- The informed consent process, which makes sure you understand the trial and its risks before you agree to join.
- Careful review and approval of the trial's protocol, the detailed plan for how the study will run.
- Ongoing monitoring throughout the trial, to catch problems as they arise.
None of these stands alone. Together, they create multiple checkpoints where a trial's safety gets examined, not just once, but repeatedly.
Institutional Review Boards
Before a trial can enroll anyone, an Institutional Review Board, or IRB, reviews its protocol. The IRB checks that the trial is well-designed, legal, ethical, free of unnecessary risks, and includes a clear safety plan. This isn't a one-time check — IRBs review ongoing trials at least once a year as well, not just at the start.
Each IRB includes at least 5 members, and by design, that group isn't made up only of scientists. It must include a scientist, a non-scientist, and someone who isn't affiliated with the trial site at all. This mix of perspectives is meant to catch concerns that a purely scientific review might miss. If an IRB has concerns, it has the authority to require changes to a trial, or to stop it altogether.
Data and Safety Monitoring Boards
Especially in phase 3 trials, an independent group called a Data and Safety Monitoring Board, or DSMB, keeps watch over the trial's safety data as it comes in. Because DSMB members are independent of the research team running the trial, they can look at emerging results with fresh eyes and flag safety concerns early. If needed, a DSMB has the authority to recommend stopping a trial before it's scheduled to end.
The FDA's role
The FDA is also involved in cancer clinical trials, particularly when a trial involves a drug that could eventually be approved for wider use. The FDA approves new drugs and works to protect the integrity of the data collected during trials, adding another layer of oversight beyond the trial site itself.
Why some trials end early
Given all this oversight, a trial can be stopped before its planned end date, and that's not necessarily a bad sign. Trials are stopped early for two very different reasons: because a treatment is clearly working, so that other patients can gain access to it sooner rather than waiting for the trial to formally conclude, or because a treatment is clearly not working, so that participants aren't kept on an ineffective approach any longer than necessary.
What this means if you're considering a trial
All of these safeguards exist so that joining a clinical trial doesn't mean stepping into the unknown without protection. If you're weighing whether to take part in a specific trial, it's reasonable to ask who reviewed its protocol, whether a DSMB is monitoring it, and what would trigger it being stopped early.
Words to know
Tap any term to see what it means.
Common questions
▸Who protects my safety in a clinical trial?
Several groups work together: the informed consent process makes sure you understand the trial, an Institutional Review Board reviews and approves the trial protocol, and ongoing monitoring — sometimes by an independent Data and Safety Monitoring Board — watches over the trial as it runs. The FDA also oversees drug approval and data integrity.
▸What is an Institutional Review Board?
An Institutional Review Board, or IRB, is a group that reviews a trial's protocol before it can enroll participants and at least once a year afterward. It checks that the trial is well-designed, legal, ethical, free of unneeded risks, and has a safety plan. Each IRB has at least 5 members, including a scientist, a non-scientist, and someone unaffiliated with the trial site.
▸What is a Data and Safety Monitoring Board?
A Data and Safety Monitoring Board, or DSMB, is a group of independent experts, especially common in phase 3 trials, who monitor a trial's safety data and can recommend stopping it early if needed.
▸Can a clinical trial be stopped early?
Yes. A trial can be stopped early if a treatment is clearly effective, so that others can gain access to it sooner, or if it's clearly not effective, to spare participants from an ineffective treatment.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Test your knowledge
0 of 4 answered
This quiz checks understanding of educational content only. It is not medical advice. Open this quiz on its own page.
How this page was created
Cancer Explained uses AI to organize and translate information from the authoritative sources cited on each page. Automated checks review claims, citations, clarity, duplication, and potential safety concerns before publication. Our content is not currently reviewed by physicians unless a specific qualified reviewer is named on the page. Cancer Explained provides general education and should not replace advice from your healthcare team.
Editorial status: Source verified — This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
Human medical review: not completed. At this time, most Cancer Explained content has not been reviewed by a physician or other healthcare professional. Pages with documented human medical review identify the reviewer, credentials, and review date directly.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.